Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Navidea Biopharmaceuticals Inc (NAVB) USD0.001

Sell:$3.90 Buy:$3.93 Change: $0.1 (2.52%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$3.90
Buy:$3.93
Change: $0.1 (2.52%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$3.90
Buy:$3.93
Change: $0.1 (2.52%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Company focuses on two types of drug products diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of Manocept platform, and NAV4694; and therapeutic development programs, including therapeutic applications of Manocept platform.

Contact details

Address:
4995 Bradenton Ave Ste 240
DUBLIN
43017-3552
United States
Telephone:
+1 (614) 7937500
Website:
https://www.navidea.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NAVB
ISIN:
US63937X2027
Market cap:
$89.63 million
Shares in issue:
23.53 million
Sector:
Biotechnology
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Michael Rice
    Independent Chairman of the Board
  • Jed Latkin
    Chief Executive Officer, Chief Financial Officer, Chief Operating Officer
  • Michael Rosol
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.